These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8027323)

  • 1. Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.
    Jones RN
    J Clin Microbiol; 1994 Apr; 32(4):1104-6. PubMed ID: 8027323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
    Neu HC; Chin NX; Huang HB
    Antimicrob Agents Chemother; 1993 Mar; 37(3):566-73. PubMed ID: 8460925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretive criteria of antimicrobial disk susceptibility tests with cefpodoxime.
    Grimm H
    Infection; 1991; 19(5):380-2. PubMed ID: 1800381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992; 15(8):693-701. PubMed ID: 1478050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN; Barrett MS; Biedenbach DJ
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN; Erwin ME; Barrett MS
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
    Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
    J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Sep; 25(9):1796-9. PubMed ID: 3654953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of FK-037, a new cephalosporin antibiotic.
    Clarke AM; Zemcov SJ; Hubinette MM
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):27-32. PubMed ID: 7867295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
    Jones RN; Zurenko GE
    Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the Rapid Lumi 'Eiken' using chemiluminescent assay for rapid antimicrobial susceptibility testing].
    Kohara T; Ueoka E; Koshobu K; Shigekawa K; Arita K
    Jpn J Antibiot; 2002 Jun; 55(3):281-90. PubMed ID: 12199112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of FK-037, a novel parenteral cephalosporin, against bacterial isolates from neutropenic cancer patients.
    Dholakia N; Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):679-85. PubMed ID: 7813504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
    Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
    Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests.
    Barry AL; Jones RN; Thornsberry C; Gavan TL; Gerlach EH; Sommer HM
    Eur J Clin Microbiol; 1984 Dec; 3(6):531-7. PubMed ID: 6441709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.
    Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE
    J Clin Microbiol; 1982 May; 15(5):769-76. PubMed ID: 6212595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activity of FK-037, a new broad spectrum injectable cephalosporin.
    Wise R; Andrews JM; Thornber D
    J Antimicrob Chemother; 1994 Nov; 34(5):629-37. PubMed ID: 7706158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin.
    Qadri SM; Ueno Y; Saldin H; Cunha BA
    Chemotherapy; 1993; 39(2):112-9. PubMed ID: 8458243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem.
    Shungu DL; Cerami AT; Weinberg E; Capizzi T; Gadebusch HH
    J Clin Microbiol; 1986 Mar; 23(3):421-4. PubMed ID: 3514655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.